Recursion Pharmaceuticals
Includes Exscientia.
Data as of .
Company facts
-
Founded
2013
-
Headquarters
United States (Salt Lake City, UT)
Latest funding round
- Round
- Underwritten public offering
- Date
- Oct 15, 2026
- Amount
- $200M
Drug discovery partners
3 pharma. Pharma here means a company with approved products and roughly $1B or more in annual revenue.
-
Sanofi Pharma
Partnership milestone,
$10M milestone payment ($144M in upfront and milestone payments to date)
-
Roche (Genentech) Pharma
Neuroscience target delivery milestone,
Terms not disclosed
-
Bayer Pharma
Oncology research collaboration,
Terms not disclosed
Drugs on the board
- REC-7735 (PI3Ka H1047R)
Phase 1/2 registry
Solid tumors (PI3Ka H1047R-mutant; breast cancer focus per earlier pipeline updates)
- REC-1245
Phase 1/2 registry
Unresectable, locally advanced or metastatic cancers; relapsed or refractory lymphomas
- REC-3565 (MALT1 inhibitor)
Phase 1 registry
Relapsed or refractory B-cell malignancies, including CLL/SLL and Waldenström's macroglobulinemia
- REC-617 (CDK7 inhibitor)
Phase 1/2 registry
Advanced solid tumors
Show all (5)
- REC-4539 (LSD1 inhibitor)
Phase 1 registry
Small cell lung cancer and other select solid tumors
Recent news
-
Sanofi partnership milestone and oversubscribed $200M offering
-
First neuroscience target delivered in Genentech collaboration
-
Q2 2026 results and business update
-
Q3 2025 results and a CEO transition plan effective January 1, 2026
-
First patient dosed in Phase 1 of REC-3565 (MALT1 inhibitor) for B-cell lymphomas
Confirmed means the company, a partner or a filing said it. Reported means a third party said it. This section sits outside the Pharma AI Tracker.
Spot an error? Tell me and I'll fix it.